Abstracts tagged "Interleukins"

Abstract Number: 0880 • ACR Convergence 2024
Investigating the SRPK-1-VEGF-A Alternative Splicing Pathway AsaTherapeutic Target in Arthritis
Charles Besidonne¹, Andrew Benest¹, Kim Chisholm¹, Jonathan Morris², Lucy Donaldson³, Jeanette Woolard⁴ and David Bates¹, ¹University of Nottingham, Nottingham, United Kingdom, ²University of New South Wales, New South Wales, New South Wales, Australia, ³Versus Arthritis UK, Nottingham, United Kingdom, ⁴University of Nottingham, Nottingham, England, United Kingdom
Background/Purpose: Alternative pre-mRNA splicing of Vascular Endothelial Growth Factor-A (VEGF-A) produces pro-angiogenic (VEGF-Axxxa) or anti-angiogenic (VEGF-Axxxb) isoforms that contribute to angiogenesis in inflammatory arthritis. Isoform…
Abstract Number: 0920 • ACR Convergence 2024
TGF-β Activated Kinase 1 Inhibition by Pentagalloyl Glucose Inhibits NLRP3 Inflammasome Formation and Ameliorates MSU-Induced Inflammation
Paul Panipinto¹ and Salahuddin Ahmed², ¹Washington State University College of Pharmaceutical Science and Molecular Medicine, Spokane, WA, ²Washington State University, Spokane, WA
Background/Purpose: Monosodium urate (MSU)-induced inflammation is caused by the deposition of MSU crystals in the joints and periarticular tissues under conditions of hyperuricemia. These deposits…
Abstract Number: 1197 • ACR Convergence 2024
Safety and Immunogenicity of an Active Anti-IL-6 Immunotherapy in a Phase 1 Clinical Trial in Knee Osteoarthritis Patients
François Rannou¹, Christelle Nguyen¹, Camille Daste¹, Quentin Kirren¹, marie-martine Lefevre-Colau¹, Odile Launay², Lucille Desallais³, Edita Dolimier³, René Azoulai³, Jean-Pierre Salles³ and Jean-François Zagury⁴, ¹AP-HP. Centre-Université Paris Cité, Hôpital Cochin, Service de Rééducation et de Réadaptation de l'Appareil Locomoteur et des Pathologies du Rachis, Paris, Ile-de-France, France, ²Centre d’Investigation Clinique en Vaccinologie (CIC Cochin Pasteur), Hôpital Cochin, Paris, Ile-de-France, France, ³Peptinov, Paris, Ile-de-France, France, ⁴Laboratoire Génomique, Bioinformatique, et Chimie Moléculaire, EA 7528, Chaire de Bioinformatique, Conservatoire National des Arts et Métiers, Paris, Ile-de-France, France
Background/Purpose: Interleukin-6 (IL-6) is a major inflammatory cytokine involved in pain and potentially in osteoarthritis (OA) disease progression. PPV-06 is an IL-6-derived peptide coupled with…
Abstract Number: 1385 • ACR Convergence 2024
A Novel Oral 3D-Printed Delayed- and Extended-Release Tofacitinib (T19) for the Treatment of Rheumatoid Arthritis and Related Inflammatory Diseases
Yue Zhou, Meng Ji, luo wang, Feihuang Deng, Senping Cheng, Xiaoling Li and Yulian Zhang, Triastek, Inc., Nanjing, China (People's Republic)
Background/Purpose: Patients with inflammatory diseases, such as rheumatoid arthritis (RA), frequently continue to suffer from morning symptoms despite treatment with conventional therapies 1,2. Routine morning…
Abstract Number: 1462 • ACR Convergence 2024
Comparison of On-Label Treatment Persistence in Real-World Patients with Psoriatic Arthritis Receiving Guselkumab versus Subcutaneous IL-17A Inhibitors
Philip Mease¹, Ruizhi Zhao², Shannon Ferrante³, Natalie J. Shiff⁴, Pavithra Srinivas⁵, Soumya Chakravarty⁶ and Jessica A Walsh⁷, ¹Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, ²Janssen Scientific Affairs, LLC, Titusville, NJ, ³Janssen Scientific Affairs, LLC, Horsham, PA, ⁴Janssen Scientific Affairs, LLC / University of Saskatchewan, Adjunct, Community Health and Epidemiology, Horsham, PA, ⁵Janssen Scientific Affairs LLC, Horsham, PA, ⁶Janssen Scientific Affairs, LLC, Horsham/ Drexel University College of Medicine, Philadelphia, Horsham, PA, ⁷Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT
Background/Purpose: Guselkumab, a fully human IL-23p19-subunit inhibitor, has demonstrated significant and durable efficacy and high rates of patient retention in randomized controlled trials of adults…
Abstract Number: 1464 • ACR Convergence 2024
Guselkumab and IL-17 Inhibitors Show Comparable Treatment Persistence and Effectiveness in Psoriatic Arthritis: 6-month Interim Results of the PsABIOnd Observational Cohort Study
Laure Gossec¹, Mohamed Sharaf², Xenofon Baraliakos³, Mitsumasa Kishimoto⁴, Ennio Lubrano⁵, Proton Rahman⁶, Emmanouil Rampakakis⁷, László Köleséri⁸, Minni Koivunen⁹, Frederic Lavie¹⁰, Enrique R. Soriano¹¹, Ruben Queiro Silva¹², Frank Behrens¹³ and Stefan Siebert¹⁴, ¹Sorbonne Université, Paris, France, ²Johnson & Johnson, Middle East FZ LLC, Dubai, UAE, Dubai, United Arab Emirates, ³Rheumazentrum Ruhrgebiet Herne, and Ruhr-University Bochum, Bochum, Germany, ⁴Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan, ⁵Vincenzo Tiberio Department of Medicine and Health Sciences, University of Molise, Campobasso, Italy, ⁶Memorial University of Newfoundland, Faculty of Medicine, Division of Rheumatology, St. John's, Canada, ⁷McGill University, Department of Pediatrics / Scientific Affairs, JSS Medical Research Inc., Montreal, QC, Canada, ⁸Data Sciences Staffing Solutions, IQVIA, Inc, Budapest, Hungary, ⁹Janssen Cilag Oy, Espoo, Finland, Espoo, Finland, ¹⁰Janssen Cilag Global Medical Affairs, Immunology Global Medical Affairs, Issy les Moulineaux, France, ¹¹Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ¹²Rheumatology Division, Hospital Universitario Central de Asturias, Oviedo University School of Medicine, Oviedo, Spain, ¹³University Hospital Goethe University Frankfurt and Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt, Germany, ¹⁴School of Infection and Immunity, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Many drugs are available in PsA and have demonstrated efficacy in randomized controlled trials (RCTs); however, real-world long-term data of drugs are scarce. PsABIOnd…
Abstract Number: 1566 • ACR Convergence 2023
Exposure-Response Analysis of Sarilumab in Patients with Polymyalgia Rheumatica
Christine Xu¹, Ying Liu¹, Jennifer Sloane², Remco Diab³, Hubert van Hoogstraten¹, Hisham Abdallah⁴, Sreeraj Macha¹ and Bhaskar Dasgupta⁵, ¹Sanofi, Bridgewater, NJ, ²Sanofi, Cambridge, MA, ³Sanofi, Rotkreuz, Switzerland, ⁴Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁵Anglia Ruskin University, East Anglia, United Kingdom
Background/Purpose: Sarilumab blocks interleukin-6 (IL-6) from binding to the membrane-bound and soluble IL-6 receptor-α subunit (IL-6Rα). Sarilumab is now approved for both rheumatoid arthritis (RA)…
Abstract Number: 2539 • ACR Convergence 2023
Baseline IL-10 Levels as a Predictive Biomarker for Achieving Clinical Response with Abatacept in ACPA+ Patients with Early RA
Jinqi Liu¹, Yicong Li², Kai Fu¹, Chun Wu¹, Peter Schafer³, Sean Connolly¹, Ian M. Catlett⁴, Michael Maldonado¹, Robert Wong⁵, Paul Emery⁶, Yoshiya Tanaka⁷, Vivian Bykerk⁸, Clifton Bingham⁹, Thomas Huizinga¹⁰ and Roy Fleischmann¹¹, ¹Bristol Myers Squibb, Princeton, NJ, ²Parexel International, Durham, NC, ³Bristol Myers Squibb, Belle Mead, NJ, ⁴Bristol Myers Squibb, Pennington, NJ, ⁵Bristol Myers Squibb (at the time of analysis), Princeton, NJ, ⁶Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁷University of Occupational and Environmental Health, Kitakyushu, Japan, ⁸Department of Rheumatology, Hospital for Special Surgery, New York, NY, ⁹Division of Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore, MD, ¹⁰Leiden University Medical Center, Leiden, Netherlands, ¹¹Division of Rheumatology, University of Texas Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: A key target of RA treatment is to achieve early and sustained remission in order to ensure lower levels of long-term structural joint damage…
Abstract Number: 0012 • ACR Convergence 2023
Immune-cell Derived Cytokines Synergistically Interact to Drive Synovial Fibroblast Invasive Function and Metabolic Capacity
Órla Tynan¹, Achilleas Floudas², Nuno Neto³, Michael Monaghan³, Siobhán Wade⁴, Dumitru Anton⁵, Carl Orr⁶, Douglas Veale⁷ and Ursula Fearon⁸, ¹Molecular Rheumatology Department, Trinity Biomedical Sciences Institute, Trinity College Dublin, Ireland, EULAR Centre for Arthritis and Rheumatic Diseases, St Vincent University Hospital, University College Dublin, Dublin, Ireland, ²Dublin City University, Dublin, Ireland, ³Department of Mechanical and Manufacturing Engineering, Trinity College Dublin, Dublin, Ireland, ⁴Molecular Rheumatology Department, Trinity Biomedical Sciences Institute, Trinity College Dublin, Ireland EULAR Centre for Arthritis and Rheumatic Diseases, St Vincent University Hospital, University College Dublin, Dublin, Ireland, ⁵Molecular Rheumatology Department, Trinity Biomedical Sciences Institute, Trinity College Dublin, EULAR Centre for Arthritis and Rheumatic Diseases, St Vincent University Hospital, University College Dublin, Dublin, Ireland, ⁶EULAR Centre for Arthritis and Rheumatic Diseases, St Vincent University Hospital, University College Dublin, Dublin, Ireland, ⁷St.Vincent's University Hosp, Dublin, Ireland, ⁸Trinity College Dublin, Dublin, Ireland
Background/Purpose: Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA) encompass two of the most common forms of Inflammatory Arthritis. While common pathogenic mechanisms are involved in…
Abstract Number: 1571 • ACR Convergence 2023
Tocilizumab in Pregnant Takayasu Arteritis – The Use of Tocilizumab at Conception and Throughout Pregnancy in Those with Takayasu Arteritis
Nurul Aulia Zakaria¹, Andrew Porter², Robert Maughan², Charis Pericleous², Japna Satara³, Matthew Colquhoun⁴, Priyanka Agrawal³, jan Nouza³, Harold Wilson-Morkeh³, Taryn Youngstein² and Justin Mason², ¹National Heart & Lung Institute, Imperial College London, Kuantan, Malaysia, ²National Heart & Lung Institute, Imperial College London, London, United Kingdom, ³Rheumatology, Hammersmith Hospital, London, United Kingdom, ⁴Department of Rheumatology, Imperial College Healthcare Trust, London, United Kingdom
Background/Purpose: Takayasu arteritis (TA) is a large vessel vasculitis predominantly affecting female of reproductive age. Tocilizumab (TCZ) is frequently used in synthetic DMARD refractory cases.…
Abstract Number: 2548 • ACR Convergence 2023
Low Uveitis Rates in Patients with Axial Spondyloarthritis Treated with Bimekizumab: Pooled Results from Phase 2b/3 Trials
Martin Rudwaleit¹, Matthew A. Brown², Floris Van Gaalen³, Nigil Haroon⁴, Lianne Gensler⁵, Carmen Fleurinck⁶, Alexander Marten⁷, Ute Massow⁸, Natasha De Peyrecave⁹, Thomas Vaux¹⁰, Katy White¹⁰, Atul Deodhar¹¹ and Irene van der Horst-Bruinsma¹², ¹University of Bielefeld, Klinikum Bielefeld, Bielefeld, Germany, ²Genomics England, London, United Kingdom, ³Leiden University Medical Center, Department of Rheumatology, Leiden, Netherlands, ⁴University of Toronto, University Health Network, Schroeder Arthritis Institute, Department of Medicine/Rheumatology, Toronto, ON, Canada, ⁵University of California San Francisco, Department of Medicine, Division of Rheumatology, San Francisco, CA, ⁶UCB Pharma, Oosterzele, Belgium, ⁷UCB Pharma, Monheim, Germany, ⁸UCB Pharma, Monheim am Rhein, Germany, ⁹UCB Pharma, Brussels, Belgium, ¹⁰UCB Pharma, Slough, United Kingdom, ¹¹Division of Arthritis and Rheumatic Disease, Oregon Health & Science University, Portland, OR, ¹²Radboud University Medical Centre, Department of Rheumatology, Nijmegen, Netherlands
Background/Purpose: Acute anterior uveitis ('uveitis'), or 'iritis', is a common extra-musculoskeletal manifestation among patients (pts) with axial spondyloarthritis (axSpA).1 IL-17 has been implicated in the…
Abstract Number: 0084 • ACR Convergence 2023
Excess IL-18 Protects from Experimental Autoimmune Encephalomyelitis Mainly via Preferential Augmentation of Suppressor/Regulatory over Autoreactive T-cell Function
Jeremy Morrissette¹, Vinh Dang², Jemy Varghese², Zachary Lanzar¹, Junior Nguyen², Emily Landy³, Anastasia Frank-Kamenetskii⁴ and Scott Canna², ¹University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, ²Children's Hospital of Philadelphia, Philadelphia, PA, ³University of Pittsburgh, Pittsburgh, PA, ⁴CHOP/UPENN, Philadelphia, PA
Background/Purpose: Interleukin 18 (IL-18) is an inflammasome-activated cytokine that canonically amplifies interferon-gamma (IFNg) production and cytotoxicity by CD8 T-cells (CD8Ts) and Th1 CD4 T-cells (CD4Ts).…
Abstract Number: 1601 • ACR Convergence 2023
Interleukin-6 Disrupts Blood-cerebrospinal Fluid Barrier Permeability in Murine Neuropsychiatric Lupus
Joshua Reynolds¹, Lola Torz², Natalia Petersen², Ayal Ben-Zvi³ and Chaim Putterman¹, ¹Albert Einstein College of Medicine, Bronx, NY, ²Novo Nordic, Global Obesity Research, Malov, Denmark, ³Hebrew University of Jerusalem, Jerusalem, Israel
Background/Purpose: In exploring the pathogenic mechanisms underlying neuropsychiatric lupus (NPSLE), it was discovered that cerebrospinal fluid (CSF) from lupus patients often contains neurotoxic antibodies, cytokines,…
Abstract Number: 2569 • ACR Convergence 2023
Efficacy and Safety of Therapeutic Interventions for the Treatment of Still’s Disease: A Systematic Review and Meta-analysis Informing the EULAR/PReS Recommendations for the Diagnosis and Management of Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still’s Disease
Sara Bindoli¹, Arianna De Matteis², STEPHANE MITROVIC³, Bruno Fautrel⁴, Loreto Carmona⁵, Fabrizio De Benedetti⁶ and On Behalf Of The Eular/PreS QoC011 Task Force Member⁷, ¹Rheumatology Unit, Dept of Medicine, University of Padova, Padova, Italy, ²IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Italy, ³Pitie Salpetriere Hospital, Sorbonne University, APHP, Paris, France, ⁴Sorbonne Université APHP, Paris, France, ⁵Instituto de Salud Musculoesquelética (InMusc), Madrid, Spain, ⁶Bambino Gesu Children's Hospital, Division of Rheumatology, Rome, Italy, ⁷EULAR/PReS QoC011 Task Force members are: Jordi Anton, Alexandre Belot, Claudia Bracaglia, Tamas Constantin, Lorenzo Dagna, Alessandro De Bartolo, Eugen Feist, Dirk Foell, Marco Gattorno, Sophie Georgin-Lavialle, Roberto Giacomelli, Alexei Grom, Yvan Jamilloux, Katarina Laskari, Calin Lazar, Francesca Minoia, Peter Nigrovic, Filipa Oliveira Ramos, Seza Ozen, Pierre Quartier-dit-Maire, Piero Ruscitti, Erdal Sag, Sinisa Savic, Marie-Elise Truchetet, Bas Vastert, Tanita Wilhelmer, Carine Wouters., Paris, France
Background/Purpose: To investigate the efficacy and safety of therapies currently in use and under evaluation for systemic Juvenile Idiopathic Arthritis (sJIA) and Adult-Onset Still's disease…
Abstract Number: 0090 • ACR Convergence 2023
Reduced Frequency of RORγt+ Regulatory T Cells Is Associated with Secukinumab Response in Axial Spondyloarthritis
Addison Pacheco¹, Michael Tang¹, Sinead Maguire², Melissa Lim¹, Fataneh Tavasolian³, Zoya Qaiyum⁴ and Robert Inman¹, ¹University Health Network, Toronto, ON, Canada, ²Toronto Western Hospital, Toronto, ON, Canada, ³Krembil Research Institute, University Health Network, Toronto, ON, Canada, ⁴Krembil Research Institute, Toronto, ON, Canada
Background/Purpose: Axial spondyloarthritis (AxSpA) is an inflammatory disease that predominantly affects the spine and the sacroiliac joints. Dysregulation of Type 3 immunity has been implicated…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].